Mimotope vaccine efficacy gets a "boost" from native tumor antigens

Tumor-associated antigen (TAA)-targeting mimotope peptides exert more prominent immunostimulatory functions than unmodified TAAs, with the caveat that some T-cell clones exhibit a relatively low affinity for TAAs. Combining mimotope-based vaccines with native TAAs in a prime-boost setting significan...

Descripción completa

Detalles Bibliográficos
Autores principales: Buhrman, Jonathan D., Slansky, Jill E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2013
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3654579/
https://www.ncbi.nlm.nih.gov/pubmed/23734309
http://dx.doi.org/10.4161/onci.23492
_version_ 1782269583999107072
author Buhrman, Jonathan D.
Slansky, Jill E.
author_facet Buhrman, Jonathan D.
Slansky, Jill E.
author_sort Buhrman, Jonathan D.
collection PubMed
description Tumor-associated antigen (TAA)-targeting mimotope peptides exert more prominent immunostimulatory functions than unmodified TAAs, with the caveat that some T-cell clones exhibit a relatively low affinity for TAAs. Combining mimotope-based vaccines with native TAAs in a prime-boost setting significantly improves antitumor immunity.
format Online
Article
Text
id pubmed-3654579
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Landes Bioscience
record_format MEDLINE/PubMed
spelling pubmed-36545792013-06-03 Mimotope vaccine efficacy gets a "boost" from native tumor antigens Buhrman, Jonathan D. Slansky, Jill E. Oncoimmunology Author's View Tumor-associated antigen (TAA)-targeting mimotope peptides exert more prominent immunostimulatory functions than unmodified TAAs, with the caveat that some T-cell clones exhibit a relatively low affinity for TAAs. Combining mimotope-based vaccines with native TAAs in a prime-boost setting significantly improves antitumor immunity. Landes Bioscience 2013-04-01 2013-04-01 /pmc/articles/PMC3654579/ /pubmed/23734309 http://dx.doi.org/10.4161/onci.23492 Text en Copyright © 2013 Landes Bioscience http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
spellingShingle Author's View
Buhrman, Jonathan D.
Slansky, Jill E.
Mimotope vaccine efficacy gets a "boost" from native tumor antigens
title Mimotope vaccine efficacy gets a "boost" from native tumor antigens
title_full Mimotope vaccine efficacy gets a "boost" from native tumor antigens
title_fullStr Mimotope vaccine efficacy gets a "boost" from native tumor antigens
title_full_unstemmed Mimotope vaccine efficacy gets a "boost" from native tumor antigens
title_short Mimotope vaccine efficacy gets a "boost" from native tumor antigens
title_sort mimotope vaccine efficacy gets a "boost" from native tumor antigens
topic Author's View
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3654579/
https://www.ncbi.nlm.nih.gov/pubmed/23734309
http://dx.doi.org/10.4161/onci.23492
work_keys_str_mv AT buhrmanjonathand mimotopevaccineefficacygetsaboostfromnativetumorantigens
AT slanskyjille mimotopevaccineefficacygetsaboostfromnativetumorantigens

Ejemplares similares